Director of the Research and Development Institute
Carroll Group: High Consequence Emerging Viruses Group
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomic A. et al, (2022), Nature Communications, 13
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Donovan-Banfield I. et al, (2022), Nat Commun, 13
An introduction to the Marburg virus vaccine consortium, MARVAC.
Cross RW. et al, (2022), PLoS pathogens, 18
Avatar Mice Underscore the Role of the T Cell-Dendritic Cell Crosstalk in Ebola Virus Disease and Reveal Mechanisms of Protection in Survivors.
Rottstegge M. et al, (2022), Journal of virology
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.
Wing PAC. et al, (2022), PLoS pathogens, 18